Atrial Fibrillation Trial, Recruiting NCT06630936 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT06630936
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 80 years of age
  • People who have been diagnosed with symptomatic paroxysmal atrial fibrillation (an irregular heartbeat that comes and goes) with a history of less than 5 years
  • People who have moderate to severe mitral regurgitation (a leaky heart valve) with normal heart pumping function and normal heart wall movement, meeting specific heart measurement thresholds (confirm with trial site)
  • People who are willing and able to understand the trial's purpose, sign a consent form (either personally or through a legal representative), and attend all required follow-up visits

Who may not be able to join:

  • People whose atrial fibrillation is caused by an electrolyte imbalance, thyroid condition, or another reversible (treatable) cause
  • People with active infection of the heart valves (endocarditis) or active rheumatic heart disease, or whose leaky mitral valve is a result of either of these conditions
  • People who have moderate to severe narrowing of the mitral valve (mitral stenosis)
  • People whose imaging scans show a blood clot in the left side of the heart or in the left atrial appendage (a small pouch in the heart)
  • People whose heart pumping strength is below 50%
  • People whose left atrial chamber measures more than 50mm
  • People who have previously had certain heart procedures, including closure of the left atrial appendage, closure of a hole between the upper heart chambers, or certain valve repairs (applies to some participants — confirm with trial site)
  • People who have an implanted heart device such as a defibrillator, pacemaker, or cardiac resynchronisation therapy device
  • People who have previously had a metal artificial heart valve or a valve repair device implanted (applies to some participants — confirm with trial site)
  • People who have abnormalities such as blood clots, tumours, or other issues near the blood vessels that would interfere with the procedure (applies to some participants — confirm with trial site)
  • People who cannot take blood-thinning medications, or who have a history of abnormal blood clotting or bleeding
  • People who have an active infection anywhere in the body
  • People who are pregnant, breastfeeding, or unable to use contraception during the study period
  • People whose life expectancy is less than 12 months
  • People who have other conditions or abnormalities that the trial investigators consider would make participation unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jianan Wang, Dorctor, Second Affiliated Hospital of Zhejiang University, School of Medicine

Phone: 086-571-87784705

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
27 September 2024
Est. completion
31 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Improvement in MR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov